Importance of Clinical Partnerships in Ensuring Quality Safety of Point-of-Care-Testing

CDC
258 followers
Dec 11, 2025
This webinar discusses the importance of laboratory and testing professionals building and sustaining strong relationships with their partners. It emphasizes how those partner relationships ensure that laboratory and testing communities keep prioritizing quality and safety.
This video can also be viewed at
https://reach.cdc.gov
[music]
Okay, [music] everyone, we can go ahead
and get started. My name is Sophie Maria
and I'm a consultant with Guide House
supporting CDC's one lab initiative. A
couple of notes about the webinar before
we dive in. If you are experiencing any
technical issues during the webinar,
please feel free to email the onelab
inbox for support at oneabcdc.gov.
If you have questions throughout the
session, please insert them into the Q&A
function below, which is represented by
the Q&A icon. We'll conduct a Q&A
session at the end of this presentation
where we will review questions and do
our best to provide answers.
Please note that I posted the link to
the live captions in the chat. However,
please ensure that both the captions
window and this webinar window remain
open if you choose to use them.
Today, we'll start by discussing new one
lab resources. Then, we'll introduce
today's presenter. We'll have about a
10-minute Q&A session at the end where
we'll review questions and do our best
to answer. And then today's session will
end with a discussion of upcoming
events.
For today's webinar, we will be leaving
the chat box open for your engagement.
When you're using the chat box, please
adhere to the established rules of
engagement. You can feel free to use the
chat to connect with others by reacting
to what you're hearing, sharing your
experiences, and asking questions to
fellow participants. If you have a
question for the presenter, please use
the Q&A function, not the chat.
Additionally, please engage with respect
and professionalism. Any inappropriate
language, improper conduct or form of uh
excuse me, discrimination may result in
removal from the webinar.
If a moderator provides direction
regarding chat behavior, please comply
accordingly. Lastly, please notify
moderators if you experience technical
difficulties or observe any disruptive
behavior. I will now turn it over to our
wind lab lead, Alicia Branch, to share
some of our new and relevant resources.
Thank you, Sophie. Before we start the
main presentation, I would like to take
a moment to share the free educational
materials from Ready Set Test, a helpful
one lab resource related to today's
topic. The ready set test resources
include a booklet, a self assessment
checklist, and an e-learning course,
which are valuable tools for training
health care professionals or individuals
without a health care background who
conduct patient testing under a clear
certificate of waiver.
Now, the booklet includes forms and logs
that can be used regardless of the point
of care testing methods or the location
where tests are conducted as well as a
self assessment um checklist for best
testing practices.
The booklet and the um checklist can be
downloaded or obtained in hard copy by
clicking the link in the chat.
The e-learning course is a
scenario-based training that explains
the steps of the wave testing process.
After completing the course, one and a
half contact hours of PACE credit can be
earned. You can access the course by
clicking the link in the chat. Next
slide, please.
I will read the CDC external speaker
disclaimer statement and then introduce
today's speaker. Slide decks may contain
presentation material from panelists who
are not affiliate affiliated with CDC.
Presentation content from external
panelists may not necessarily reflect
CDC's official position on the topics
covered. Next slide, please.
I am excited to introduce our presenter
Dr. Elise U. She is board certified by
the American Board of Clinical Chemistry
and serves as the medical director
overseeing clinical chemistry iminology
toxicology point of care testing and
clinical pathology informatics at
Gisinger's health systems. She is also a
professor of pathology at Gisinger's
College of Health Sciences. In 2016, she
was named to the 40 under 40 top five by
the American Society of Clinical
Pathology. Her primary interest is
improving laboratory testing utilization
and operational efficiency. She often
speaks on porticare testing and eager is
eager to share her insights on the
importance of clinical partnerships in
ensuring quality and safety of pornicare
testing. Our one lab test presenter for
today is Dr. Ely who over to you Elise.
>> Thank you for the introduction. Let me
switch over to share my slide.
All right. Can you guys see my slide?
Thumbs up anyone?
>> Yes, we can see it.
>> Awesome. Um, again, thank you for the
introduction and invitation to speak
with you guys today. Um, this is one of
the topic that I'm really truly
passionate about and hopefully uh we can
have some good discussion at the end of
the presentation.
Um, I don't have anything to disclose.
I'll be uh mentioning a few of the point
of care testing device throughout my
presentation but I don't have any
financial support from them.
Um in my talk today I will briefly talk
about um how laboratory um who
laboratory um partner with um including
nurses, medical doctors, pharmacists uh
respiratory therapists and towards the
ends I will um talk about a slightly
different idea about thinking about
patients as someone that we partner with
directly and we'll um also go through
what um my team at Gisinger um uh does
in terms of point of care testing. Um I
I think the service that we provide
really help in terms of that uh
strengthening that partnership. Um and
throughout the presentation I'll focus
on um two general topic. One is how the
partnership help with test selection and
the other is the uh clinical testing
protocol.
Uh but first a little bit about where I
work. Um Gisinga Health System is in
central Pennsylvania. Uh we provide
continuum health care to about 4 million
people in 45 Pennsylvania county. We
have 10 hospital campuses and about 160
primary and specialty clinics.
Here's a map to help you um see where we
are. Um showing you here is the state
Pennsylvania. In dark green is uh the
our primary service area and um in red
is um upper 10 hospital that I was
mentioning about. Um and throughout the
green and these light green color uh we
have the 160 uh specialty and primary
clinic that serve our patients.
And let's zoom in on point of care
testing. Um throughout the entire
hospital system, we currently have 8,400
point of care testing operators. Um
1,000 of which also uh perform non-wave
testing um and 58 uh of them perform
provider perform microscopy.
Our test volume is about 1.4 4 million a
year. Um, of which about 800,000 is
glucose tests. About 47,000
is ISAT testing.
Beside and glucose meter, we also have
uh Clinitech to do your analysis
testing. Um, and we have coagul to do
PTINR. Um, DCA Vantage to do HBA1C.
um and a few a box meter, hemocq and
cardioen uh cardio libens tests.
We also have manual tests uh in our
system. Um they include gastroat
hemocode u mono test um pH paper for uh
fluid testing, strap a urine drug screen
and urine pregnancy tests.
So I'll next focus more on the test
selection and management part of things
and let's go through this looking at a
few cases. So in many of my clinic we
have the strap a test available for uh
physician to use. um one of the
clinician um was trying to increase the
sensitivity of the test by in by
increasing the incubation time.
So the problem with this is that first
of all we don't know if increasing the
incubation time is going to really help
improve the test accuracy. In theory, it
sounds like a good idea, but if they
wanted to do that, it's something that
we have to do a validation study. The
other complication of this is if we make
changes to the test system instruction,
the test will no longer be considered
wave test. And I'll talk about uh this a
little bit later. If we change a test
from wave to non-wave or um or LDT,
there's a lot of u regulatory work that
is involved. So, uh you can really just
change the test, but the provider
doesn't know.
And let's look at the second case. In
this case, um the nurses wanted to do an
eye test uh but didn't have a plain
syringe with her. Um, she had a saline
syringe that she found in her pocket. So
to save time, she expelled the saline in
the syringe and then dropped the blood
samples for CAM 8 testing. And this is
your first poll questions. What do you
think would happen to the lab results? I
hope you guys can see the poll that
should be showing up on your screen.
Uh, the poll should be up. I don't know
if I can see the result.
>> Elsie, it looks like 82% chose um option
C. All right, I think I'm talking to a
lot of lab people, so you guys all got
the right answer on this, which is
great. Um
but hopefully through this two example
uh you can see that the provider may
have the best intention which is they
want to get this done faster. They want
the result to be accurate as in the
first case um but they don't fully
understand the implication of what they
do um and realize that even a small
deviation in testing procedure can have
negative impact. Um so through lab
partnership uh I really think it is key
in ensuring good lab results and
preventing potential serious events uh
because when we see these type of issue
will provide additional training and
education.
Let's look at two more cases. Um many of
you may know that there's a neotraumatic
brain injury test that um is available
with ISAT infinitity. um which helps
rule out intra cerebo hemorrhage. Um so
when our provider in DMS and sport
medicine know about it, they were very
excited and want to implement it um on
the field um so they can triage patient
and save time by bringing the patients
to the ED.
But there are a couple problem with
that. Um, and this may just be a
Pennsylvania thing, but because the test
is nonwave,
um, in Pennsylvania, do actually uh
doesn't allow us to use non-wave tests
outside of a healthcare facility. Uh, so
from a regulation standpoint, it will be
very difficult to implement in the way
that they want.
Um, and this is your second poll
questions. Uh, case four. Um similar to
that um sales rep from company Y visit a
clinic and drop off a glucose meter and
test strip for trial. Um my question to
you is if they can use it to perform
patient testing.
I'll give people a minute to do the
poll. I can see the results coming
through.
So, I see that no one picked option A,
which is great. Again, I can see that
I'm must be talking to all the lab
people. Um
um even though it seems like it's a good
idea to use it because it's free. Um
from a regulation standpoint, the
biggest issue is that um the uh glucose
meter that is dropped off is not for
hospital use. Um there is very clear um
uh FDA have very clear um
um clearance on whether the the device
is clear for home use or hospital use
from a point of care testing standpoint.
Um another concern that we typically
have uh from a lab standpoint is we want
to make sure that we know if the test
results is accurate before we use it for
patients. Um and another is about
infection control. Um one of the reason
that the home use device and the
hospital device are very different is
that the home use device you don't have
to worry about too much about infection
control because it's not going to be
used by multiple people. Um but in the
hospital setting one device would be
used by uh four different patients. So,
so we always have to have infection
control protocol in place.
Um, so in the last two case, one of the
things that I wanted to highlight about
is that um tests can have um wave tests
versus non-wave. Um from a FDA
standpoint, typically when it's wave,
the test is considered simple with
minimal chance of error. Solon
manufacturers instructions are followed
to perform testing. Um and non-wave test
typically requires more advanced
training. Um from a oversight
standpoint, wave testing are a lot
easier to manage. Uh but for non-wave um
there usually are a lot more um
regulation that we need to follow.
Um one of the things for non-lab um
people who may be on the call is that um
lab regulation is complicated. Um there
is federal regulation like clear and FDA
uh regulation that we have to follow but
there's also state regulation like do
like the one that I was talking about
the new TBI test. Um Pennsylvania may be
different than your state. Um and on top
of that the accreditation bodies like
CAP or joint commission they can um they
can be a little more strict in how they
interpret those um lab regulations. Um
so it's really not all that easy to make
sure we we are compliant. Even though I
have been doing this for close to 15
years at this point, there are often
times that I still have to go back to
look at the regulations word to word to
make sure I didn't misinterpret it. Um,
finally on top of the lab regulation,
um, there are different highly
recommended guideline. The one that all
of you probably know on this call, uh,
is the CLSI guideline. uh even though
they're not considered regulation often
times um they're so highly rec uh highly
recommended that we do want to follow
them.
So one of the things that the lab does
uh is that we helps ensure regulatory
compliance. Um the two things that I was
talking about about whether a test is
wave or non-wave um um is it's one of
the first things that I always look at
when I'm thinking about point of care
testing because it also dictates uh
personnel qualification as in who um who
who can be qualified to run the test or
uh who can be the supervisor or lab
director. So all those are complicated
and on top of that um the lab also make
sure that uh we have a good uh SOP in
place um which have very clear guidance
on how often quality control needed to
be done or calibration is needed as well
as training and resource reporting to
make sure we're compliant um as well as
being able to perform the test uh as
accurate as we can be.
Um one of the questions that um actually
get asked pretty frequently is whether
wave testing requires a lab license. Um
most of you again on this call probably
know um but based on the regulation yes
even wave testing does require a clear
uh license uh in order to perform
testing.
Um so in our health system even just
with all the uh certificates um we have
close to 100 of them and we need to uh
closely monitor these certificate for
expiration dates and manage payment to
make sure we renew them in a timely
basis. Um that's one of the things that
my point of care testing team actually
um do um so then so that we can make
sure the license application is correct
as well as not expire um because of all
the um testing location. We also
coordinate with the O to um to make sure
the inspection are done. Um
and of course we help the um our
provider to understand the um
regulations um so that we can be
compliant.
Another things that my team does is to
uh have good uh standard operating
procedure. Uh we develop them um as in
we we write them and have them review it
as well as we make sure they annually
review and update it. uh and if there's
any need for changes um or make it more
clear, we also make that changes.
Quality control um our team um review
them monthly. Um to make sure that they
they are all completed and there was no
quality issues. Um we also perform
reagent verification when we get a new
lots of reagent. Um and we also make
sure the device is set up uh in such a
way that when QC is out uh it will be
shown on the device. So uh the user
knows that the quality metric is not
being met.
Our team also help manage um patient
testing for results that uh for device
that can be interfaced. We um work with
it to make sure that the the device is
interfaced and the results if file
incorrectly um and for tests that
doesn't have that capability, we also
work with it to set them up in our EHR.
So the provider can do uh manual edit on
the result entry field to document the
results properly.
And I think a lot of uh our users don't
fully understand setting up device
interface often is not that simple and
requires a lot of work and even after
though we after we initial set it up
often time there's a lot of maintenance
involved um and software upgrade um my
team also make sure those get done in
all our devices.
Um related to that is network
connectivity. If there's ever an issue
with which actually happen relatively
frequently um our team help
troubleshoots the issues and work with
it to resolve it. Uh we also have a um
good record um in our middleware to that
store all the patients uh information
all the patients data um the ID together
with the uh result and if you know the
the the user scan the wrong um patients
band and have the wrong result file to
the patient's chart we also make those
correction
um for the equip equipment. There's a
lot of upkeep on that. Uh we provide all
the um uh equipment maintenance for the
users and if it's broken or doesn't work
or malfunction uh we also work with um
the floor to have them replace uh if
needed. Um that a lot of inventory
management that occur for point of care
testing. Uh some of it include um like
the reagent that we talk about uh but
but it also include making sure that
nothing is expires. Uh so my team do
floor check on a monthly basis. Um and
they also um check um check the quality
of the supplies like I mentioned earlier
and um all the inventory actually all
the reagent actually come into my
central team. Um and then when the floor
need uh additional order they order from
us so we can have a better control of
the quality
for training and competency. Um we
provide uh training material and once
training is completed we will give the
um our user a batch um which have their
um uh point of care testing uh specific
ID number on it. Um and we track to make
sure that all our operators have their
competency done in a uh timely manner
and if something you know um they didn't
do something right will we'll also
provide remedial training
um on safety um like the infection
control that I was talking about with
the glucose meter um we developed those
safety policy um an audit and then we
also implement um plan if there was any
issues.
So all those um we
have provided a lot of values to our
users to enhance um test accuracy and
performance um as well as test
selection. Um what I wanted to shift
gear a little bit is about clinical
utilization. Um and in this part of it
I'll focus on talking about test. All
tests have inherently have test
limitation. It's about understanding the
test limitation so then we can prevent
error and make sure it is being used in
the right group of patients. Um and then
also talk about the need to target um a
specific group of population if we
really want to drive outcome.
Um, one of the examples that I talk a
lot about is urine drug tests. Um, I'm
showing you is one of the drug test cup
that you can find in many companies. Um,
these tests um, I mean they they they
are what they are. It's not that the
tests are bad. It's just that the the
results are considered presumptive. Um
what I meant is that they could have
false positive and or false negative. Uh
if not interpret uh carefully it could
have really bad outcome. Um for example,
we we strongly advise against using this
test for pre-employment drug screen and
the reason is that if someone have a
false positive um on this drug cup uh it
will cause someone to lose a job or
interview. Um and similarly for pay
management um it is just as just as big
of a problem. Uh the idea of pain using
a tox testing for pain management is to
make sure the patient is taking the drug
that they're supposed to be taking. Um
but often time these cup u may not
screen for the drug that you may be
interested. For example uh if your
patient is on rolin um they may not be
it well there's no cup that screen for
rlandin. uh so you'll come up as
negative and and if you misinterpret
those results sometime it could lead to
wrongful dismissal of patients uh from
the uh from their treatment program.
Um another test that we use is the PTIL
point of care testing. There are
multiple device that can do this now. Um
but we in our uh system we limited the
test to our um medication therapy
management pharmacist. Um so it's a much
smaller group to use um to manage
patient who takes uh Warframe and the
reason that we limited to a small group
of um of users was because the there is
some discordance between the PTINR on
the device uh compared to the lab the
core lab results. So if they are not uh
used to seeing the result uh that is a
possibility of um misinterpreting the
test results and then cause patient to
have the wrong dosage adjustment for
that warframe.
Um so these pharmacists were trained to
uh understand that the results are only
comparable within 20 to 25% which is
quite a big range. um they are also more
in tune with um what the results mean
and would ask the lab to recheck if
needed. Um one of the questions that
often come up um uh is that sometimes a
yei would be thinking that oh can we use
this to check if a for a stroke patients
um the answer is no as far as I'm I know
uh all the PTI and now point of kit
device out there are only clear to be
used uh for patient that is on warren
only.
Um
so the the two example that I talk about
um the main point is that I want to come
across is that the there are test
limitation on any of these devices and
it may not be always be obvious to our
providers. Um so the lab really should
communicate the limitation um to the
provider when selecting test method and
as well as during training to minimize
the issues.
Um the next things I want to talk about
is that often time we think about when
there's a test people must be using it
uh since they asked for it uh to improve
outcome. Um and that's actually not
really true. Um and I'll give I'll talk
about this example about uh our
experience in launching the HBA1CA
test. Um so the project uh we have
really good collaborator with uh the
diabetes care team as well as the guys
health plan in the system uh to launch
this project and the initial goal of the
project is really to target patients
with HBA1C
uh greater than nine. Um it takes a long
time to get the instrument setup
interface and all that. Um but even
after we have it finally set up uh we
have seen that the test wasn't being
used um as often as we thought and in
addition we didn't really see a clinical
impact uh to the patient as in the
number of patient who have high hbaw1c
remain high um so we work on it and form
multi-disipline uh team uh which include
the nutritionist pharmacist um ops
people uh the clinic staff and the case
manager.
Um what this team does is that um they
would they have a list of patient with
um with high uh HBA1C
um and each week um this team would
discuss their recommendations um for on
you know the treatment plan follow-up
plan for this patients and the
recommendation would then be reviewed
with the clinical staff and providers
during daily huddle and I think this
daily huddle is important because that
also helped the uh clinic providers um
make sure that the A1C testing is done
and with that the provider was able to
provide recommendation and exab uh to
the pro to the patient in addition these
patients are being follow up every 30
days uh with a member in the care team.
So the results was pretty dramatic. Um
we with with the launch of that uh
collaborative effort we were able to see
uh reduction of patients with high
hbaw1c
uh showing you in the graph example of
free clinic. Um the the y-axis is
showing you the percent of patient uh
with hbaw1c greater than nine. Um so you
can see that in all cases um we were
able to bring that percentage down. Um
and you can see that the result was
really dramatic in in clinic number two
uh where it was reduced from 54.3% to
26.3%.
Um so it is really important to have a
process in place in particular to to
look to see what obstacle was there and
how to overcome it and and also to be
able to see to track the clinical
effectiveness with data. Uh I think that
really help uh our users to see um how
their effort has play out.
Um and with the partnership between lab
and providers, I really think that uh we
were able to have a integrated and
coordinated care model which improve
operation and regulatory compliance as
well as enhance clinical utility of lab
testing ensures accountability for
quality care and cost and ultimately
that improve um patient experience and
care.
So, so far we have talked about patients
in a little bit indirect uh manner even
though the end goal is always to improve
their care. Um but I want to shift gear
a little bit to talk about patients as
more a direct partner.
Um at home testing um probably is not
foreign to any of you. Um many people
have used um various um at home testing
um many uh and at home testing have been
in the market for for a very long time.
For example, pregnancy test does uh
glucose test and fecal or cold blood
testing.
Um in 2027
um the world kind of changed with the uh
with uh 23me or ancestry.com arrived the
scene. Um those are the first um company
that do genetic uh testing uh and offer
at home testing.
um 2012 um HIV test was another hallmark
um uh as well as many other tests like
test kit uh drug of abuse test um and
now you can find everything including
allergy testing, fitness test and of
course uh no one will forget about COVID
19 and the uh and all the co testing
that was uh available uh for us to use.
Um, one of the things that's important
to really think about is that not all
the point all the at home testing are
equal. This is a funny articles that I
found uh from 2018. Uh, the headline is
say some genetic tests apparently can
tell if you're a good dog, if you're a
dog or human. Um, so apparently what
this um, news station did is that they
sent one reporter's DNA to a handful of
home DNA tests to compare the result.
Um, and in addition to sending the
reporter's DNA, they also send the DNA
from a lab retriever. Um while most
company was able to figure out that the
the the lab retriever samples was not
readable uh one of them um that didn't
seem to notice that and have a sevenpage
report uh praising how good the cardia
output and muscle forces is of the dog.
Um so um so hopefully this highlight
that they are not all the all the same.
While this seems to be funny, um this
other articles that I found may be more
serious. Uh I found this one in lab
economics on the September 2023 issues.
Um apparently a Massachusetts uh
residence um was considering filing a
lawsuit um and call Wells Food
Sensitivity test snake oil. um she lead
the test uh worthless and claimed that
the test results Rammy indicate uh what
she was sensitive to or what she was
allergic to. Right?
But let's look at this a little bit more
closely. Um I went to Apple's well
website and you know this just a quick
screenshot to to show you guys they have
multiple different um food related
testing. Um,
so I think it may not be easy for
someone to figure out which one to buy
if they wanted to know if they have food
allergy. Um,
at least to me, um, I mean now I know,
but at the time it's a little confusing
uh, as to what is food sensitive versus
what is food allergy test.
And then from a consumer standpoint, I
guess someone would be wondering if a
more expensive test is necessarily
better. Um, and of course, what is the
test results actually mean, right? If
you have a positive result, does it mean
that you're allergic to the food? Um, so
all in all is very confusing.
And in case you guys are wondering, uh
hopefully you can see that the food
sensitive test is the one that tests for
IGG and the LG tests for IG.
Um IGG if you think about it from your
immunology class is really a memory
antibbody. Uh positive IGG test is a
sign of normal immune system and suggest
tolerance or that you have taken the
food um not necessarily food allergy. Um
IGG test is typically not recommended
for the evaluation of food allergies.
Ig test is confusing though. Uh
typically we think about Ig test as an
allergy test but for food if you have a
IG positive food test it actually does
not necessarily mean that you are
presenting with food allergy. Uh in fact
when I talked to board certified
allergists um they said that um patients
who have a positive IG test they have a
higher risk of developing actual food
allergy if they stop eating the food. Um
so it is actually pretty convoluted and
this is actually one of the tests that
is often misused uh even by our primary
care physician. Um, what am I trying to
say? Um, if you're concerned about food
allergy, my two cents is that instead of
getting test done yourself, you may want
to uh see a board-certified allergist
physicians um to understand like whether
you truly have food allergy or you may
be prone to having food allergy and
what's the next step.
Here's
another examples uh of um
misinterpretation
of at home uh test um during um the
covid pandemic. Uh this was one of the
paper that published and showed that one
in three people misinterpret at home uh
co test. Uh in this particular incident
incidents um they're looking at people
who have a high pre-est probability. So
for example with recent contact with
infected individuals or new onset of
COVID like symptoms and a negative at
home test results. In this group of
patients 33% of people fail to
quarantine even though the standard
authorized instructions say otherwise.
And here is how the standard uh
authorized instruction um show.
And then the study um make a nicer um
interpretation guide as you see here
with um with with um you know happy face
and and and otherwise and different
color and with this interpretation guide
only 14% of people uh fail to
quarantine.
So that's a significant improvement. Um
the point is that we need to be more
consumer centric when we're trying to
communicate to our end user who may not
be uh FDA uh looking at the package
insert or another scientist. A easy to
read guide uh is really helpful.
Um with the increased use of at home
testing uh AMA which is the American
Medical Association uh also have concern
and and have this article that say
growth of self-directed testing raises
risk of patient confusion um and a lot
of it has to do with either
inappropriate uh test interpretation
which is what I was just talking about
or inappropriate test selection and
sometimes incorrect test performance.
So I I really think as lab uh
professionals um we can do more um than
than what we have been doing. I think we
we need to start thinking about um our
consumers patients uh as our partner and
provide more guidance to them to ensure
safety and quality um by assisting them
with the test selection um and how to
use the test as well as results
interpretation.
With that, I would like to end by um
just mentioning a few people um that did
a lot of the work. Uh most of the work
that I was talking about at the
beginning of my presentation
um is from my team, my point of care
testing team that was led by uh Beth
Ambrose who is our system manager uh for
that team. Um and some of the example
that I was able to show you guys I
really think um kudos to the
collaborative effort uh and culture at
Guisinger. And if you guys have any
questions, I'm happy to answer them.
Thank you, Elise. We'll take a few
minutes um to answer as many questions
as we can. If we can't address your
question today, we'll do our best to
respond by email. And if you have any
questions after today, feel free to
email the one lab inbox at
onelabcdc.gov.
Okay. Well, let's dive in.
Um presenter says, "Thank you for a
great um session. How do you document
and monitor critical results
notifications and what is the turnaround
time for notifications?
>> Um because it's point of care testing,
um that doesn't go through the central
lab for notification.
uh we rely on the users to communicate
the results directly to the clinical
team when they're on the floor.
>> Okay.
Another person says, "Fantastic
presentation with over
100.
Does each CLEA director approve the
SOPs?
uh is approval sign off via printed
binder of SOPs or documents control
systems.
>> Um so that's a good questions and um
it's somewhat complicated. Some of them
actually do sign off with our policy
manager system which is our electronic
document uh policy control um software
that we use. Um but because there are so
many of them um there are quite a few
that we still use the printed process
because it re actually is easier for the
smaller clinic.
Um have you experienced success or uh
challenges with manual test entry and
inclusion of all results reporting
requirements
such as reference intervals?
>> Yeah. Um so we set it up so that they
have to enter the QC that was one of the
challenge that we have previously where
QC was not always enter um so we set up
right now that when they enter the
patients results they also uh enter the
the quality control and the reference
intervals is preset in the um in the
electronic health record so they
wouldn't forget.
>> Okay. Um we have quite a few questions
what they wanting to know how many point
of care coordinators, supervisors and
managers do you you have?
>> I currently have one system manager and
I think I have five to six coordinator.
Um and the way we set is based on region
so then they don't have to travel too
far. So for example, I have one for the
western and I think in central region I
have two uh northwest region I have
northeast I mean I have another two um
so it's somewhere around five to six and
I'm actually working to add more because
um we're going to um take over more
point of care testing uh in the system.
Okay. To add um how much space do you
currently have to operate all your
activities that you mentioned? Do you
think you have enough space to perform
your activities? If not, what do what do
you do to overcome your shortcomings
with relationship to space needs?
>> Um
I think that's a tricky questions. I
don't think anyone would ever say they
have enough space. [laughter] Um but I
would say that what we have is pretty
nice. Um we struggle for a long time on
space and so sometimes we basically just
in the system wherever space we can
find. So it's not always right at the
lab uh is what I meant if we can find a
space elsewhere. Um recently things have
gotten better because we did build a new
cam new hospital lab for um our uh one
of our location and when we did that
that was more intentionally designed to
include space for training as well. Uh
but that's not the case for every single
one of my hospital. uh some sites like I
said we have become very um very
flexible and uh we do training on the
floor and use that space. Um so it just
depends.
>> Um
someone would like to know why was
clinic 2 much more successful than one
and three. Did they do anything
different?
>> So I don't think we did anything
different. if um in that three clinic
that I show everyone was able to hit
about twow
um in terms of the number of patients uh
who are greater than 9%. I think what it
show is that if you follow the protocol
it will get you to the baseline of about
20 low 20%
um of high A1C patient. Clinic 2 was
looks more successful from the
standpoint that they were bad to begin
with. So the changes look a lot more
dramatic.
>> Okay. Um we'll answer
about three more questions.
Um,
so
wanted to know when adding additional
wave test or removing tests that are no
longer used, what is the best route to
do this to update the CLEA agreements?
Um
I I'm not 100% sure what the question
meant. I guess they are not talking
about how to update the clear
certificate. I guess they're talking
about how to get buy in to get the
provider to understand that that may not
be the best test. Um we do that two
different ways. One is that we have a
lab testing committee. Um so things get
discussed in that testing committee and
interested um and then we will either
have you know the stakeholders say you
know Dr. Smith from clinic three clinic
3 actually have the question we may
include Dr. Smith to come to the meeting
and and discuss his concern but other
time we will just disseminate the
information to others. Uh typically if
we do remove the test um sometime we do
it uh side by side as we are able to
address it and talk to the provider at
that location. Um the other time if it's
a urgent clinical issues like there's a
recall or the company you know something
bad happened um those happen more
dramatically um those um go through the
medical director of certain group as
well as our risk um partner to make sure
those information get disseminated.
I hope I answer the questions.
Um, let's see.
Try to find one blend. That
won't kind of take a lot. Um,
this this is a a a good one. Um
they want to know how do you design
competity assessment for porn of care
testing? Um and it also is in relation
to uh this question as well. How do you
manage point of care in a clinical at a
clinical level? Um you they actually
struggle with the clinical staff in as
well in getting training for them
competency and QC documentation.
Joe,
you talked about your the size of your
your lab and I I think that they kind of
want to know how are you actually
training your staff to make sure that
they are competent in whatever the point
of care testing that they're doing.
>> Yeah. Again, um I want to make sure
people give kudos to my team who does
the actual work. Um they have actually
really good relationship with the floor.
um they tirelessly remind them that hey
your competency assessment is still
we're available at this time you know we
we'll work with your schedule and help
you get them done um some yeah I cannot
give enough kudos to my team to to make
sure like they they basically go after
people who doesn't have the competency
assessment done uh in a timely manner uh
and it and if it did happen that it and
like you know they didn't get it done
then unfortunately we do have to
escalate uh within that group to let
their their manager and director know
that hey uh the users unfortunately we
have to remove the the access to the
device because they haven't complete
this um so that's that's kind of how we
go about it the same thing as making
sure quality control is done um I think
that goes
>> that's actually have two main things
that I want to talk about one is to make
sure that your quality control program
is not overly stringent. What I mean is
if you have a test that is really good
and then if you ask them to do that
every day that may be difficult for them
to comply. But if you say okay every
Monday uh do this then maybe it's a
little bit easier to put in their
workflow. So I think it's just a matter
of making sure people understand what
the requirement is and what they can
handle and then and then go from there.
Um but my team do check to make sure
that they are done in a in a timely
manner and then again if they the floor
forgets um they'll get reminder and if
needed it will get escalated. Um yeah
that's all the time we have for
questions and I want to say thank you
Elise for an excellent presentation and
we look forward to having you back
again.
Can we pull up the slides please?
I want to briefly highlight an upcoming
one lab network event that's occurring
on August 27th at 12 PM Eastern Standard
Time. The event title is biosafety and
and microbi biological and biomemed
laboratories 6th edition updates
clinical laboratory biosafety
recommendations presented by Nancy
Cornish. The registration link is posted
in the chat.
Next slide, please. Oh, you already
changed. Thank you. As a reminder, the
slides and audio recording of this event
will be posted on one on our one lab
test website within two weeks of today.
And you can find the link to um our one
lab test website in the chat.
Next slide, please. In conclusion, we
encourage everyone to use the one lab
inbox to share your training needs and
feedback about one lab test with us. Um
we actually use your input to understand
the community training needs and to
determine the topics of our webinars.
The one um email address is posted in
the chat for easy access, but I'll give
it to you. It's one labcd.gov.
Thank you and have a great rest of your
day.
>> [music]
